Welcome to
»здательство јтмосфера

Ј ∆урналы
Ј  ниги
Ј ќ проекте

ЈЁлектронные версии книг издательства УјтмосфераФ поступили в продажу

»здательство УјтмосфераФ идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. “еперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издани€. ¬ электронной версии проще отыскать рисунок и таблицу. „тобы обратитьс€ к ним, достаточно нажать на ссылку на каждый из них. »счезла зависимость от тиража Ц вы можете приобрести даже те бестселлеры, тираж которых уже разошелс€, такие как У—аркоидозФ или У«аболевани€ органов дыхани€ при беременностиФ. ”простилось получение вами книг Ц в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ќу и наконец, цена Ц электронные версии наших книг гораздо дешевле, чем бумажные издани€. «аказывайте электронные версии книг издательства УјтмосфераФ на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



»Ќ“≈–Ќ≈“-ћј√ј«»Ќ
»здательство јтмосфера


“елефон издательства

  
Ќервные болезни
2010 / N 1

Ќейропротективный механизм действи€ 1"(R)"аминоиндана Ц основного метаболита противопаркинсонического препарата разагилина (јзилекта) (—писок литературы)


Abu-Raya S., Blaugrund E., Trembovler V., Shilderman-Bloch E., Shohami E. and Lazarovici P. (1999) Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-different PC12 cells against oxygen-glucose deprivation. J. Neurosci. Res. 58, 456Ц463.
   Abu-Raya S., Tabakman R., Blaugrund E., Trembovler V. and Lazaro- vici P. (2002) Neuroprotective and neurotoxic effects of mono- amine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur. J. Pharmacol. 434, 109Ц116.
   Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto- Nagai M., Youdim M. B. H., Tsujimoto Y. and Naoi M. (2002a) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82, 913Ц923.
   Akao Y., Maruyama W., Yi H., Shamoto-Nagai M., Youdim M. B. H. and Naoi M. (2002b) An anti-ParkinsonТs disease drug, N-prop- argyl-1(R)-aminoindan (rasagiline), enhances expression of anti- apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326, 105Ц108.
   Bar-Am O., Amit T. and Youdim M. B. (2004a) Contrasting neuropro- tective and neurotoxic actions of respective metabolites of anti-Par- kinson drugs rasagiline and selegiline. Neurosci. Lett. 355, 169Ц172.
   Bar-Am O., Yogev-Falach M., Amit T., Sagi Y. and Youdim M. B. (2004b) Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neu- rochem. 89, 1119Ц1125.
   Bar-Am O., Weinreb O., Amit T. and Youdim M. B. (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 19, 1899Ц1901. Bar-Am O., Amit T. and Youdim M. B. (2007) Aminoindan and hy- droxyaminoindan, metabolites of rasagiline and ladostigil, respec- tively, exert neuroprotective properties in vitro. J. Neurochem. 103, 500Ц508.
   Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D. E. and Mattevi A. (2005) Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic anal- ysis. J. Med. Chem. 48, 8148Ц8154.
   Carlile G. W., Chalmers-Redman R. M., Tatton N. A., Pong A., Borden K. E. and Tatton W. G. (2000) Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol. Pharmacol. 57, 2Ц12.
   Carlsson A., Adolfsson R., Aquilonius S. M., Gottfries C. G., Oreland L., Svennerholm L. and Winblad B. (1980) Biogenic amines in human brain in normal aging, senile dementia, and chronic alco- holism. Adv. Biochem. Psychopharmacol. 23, 295Ц304. Carrillo M. C., Minami C., Kitani K., Maruyama W., Ohashi K., Ya- mamoto T., Naoi M., Kanai S. and Youdim M. B. H. (2000) Enhancing effect of rasagiline on superoxide dismutase and cata- lase activities in the dopaminergic system in the rat. Life Sci. 67, 577Ц585.
   Chen J. J. and Swope D. M. (2005) Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol. 45, 878Ц894.
   Colucci M. A., Moody C. J. and Couch G. D. (2008) Natural and syn- thetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. Org. Biomol. Chem. 6, 637Ц656.
   Durkin J. P., Tremblay R., Chakravarthy B., Mealing G., Morley P., Small D. and Song D. (1997) Evidence that the early loss of membrane protein kinase C is a necessary step in the excitatory amino acid-induced death of primary cortical neurons. J. Neuro- chem. 68, 1400Ц1412.
   Ekblom J., Zhu Q. S., Chen K. and Shih J. C. (1996) Monoamine oxidase gene transcription in human cell lines: treatment with psychoactive drugs and ethanol. J. Neural Transm. 103, 681Ц692.
   Eliash S., Speiser Z. and Cohen S. (2001) Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J. Neural Transm. 108, 909Ц 923.
   Eliash S., Shteter N. and Eilam R. (2005) Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J. Neural Transm. 112, 991Ц1003.
   Finberg J. P. M., Tenne M. and Youdim M. B. H. (1981) Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect, in Monoamine Oxidase Inhibi- tors Ц The State of the Art (Youdim M. B. H. and Peykel E. S., eds), pp. 31Ц41. Wiley, Chichester.
   Finberg J. P., Lamensdorf I., Commissiong J. W. and Youdim M. B. H. (1996) Pharmacology and neuroprotective properties of rasagiline. J. Neural Transm. Suppl. 48, 95Ц101.
   Finberg J. P., Takeshima T., Johnston J. M. and Commissiong J. W. (1998) Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 9, 703Ц707.
   Gubina E., Rinaudo M. S., Szallasi Z., Blumberg P. M. and Mufson R. A. (1998) Overexpression of protein kinase C isoform epsilon but not delta in human interleukin-3-dependent cells suppresses apoptosis and induces bcl-2 expression. Blood 91, 823Ц829.
   Huang W., Chen Y., Shohami E. and Weinstock M. (1999) Neuropro- tective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Phar- macol. 366, 127Ц135.
   Kim S. H., Fountoulakis M., Cairns N. and Lubec G. (2001) Protein levels of human peroxiredoxin subtypes in brains of patients with AlzheimerТs disease and Down syndrome. J. Neural Transm. Suppl. 223Ц235.
   Lamb H. M. and Goa K. L. (2001) Rivastigmine. A pharmacoeconomic review of its use in AlzheimerТs disease. Pharmacoeconomics 19, 303Ц318.
   Maher P. (2001) How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J. Neurosci. 21, 2929Ц 2938.
   Malorni W., Giammarioli A. M., Matarrese P., Pietrangeli P., Agostinelli E., Ciaccio A., Grassilli E. and Mondovi B. (1998) Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett. 426, 155Ц159.
   Mandel S., Weinreb O., Amit T. and Youdim M. B. (2005) Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Brain Res. Rev. 48, 379Ц387.
   Maruyama W., Akao Y., Youdim M. B. H. and Naoi M. (2000a) Neu- rotoxins induce apoptosis in dopamine neurons: protection by N- propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm. Suppl., 171Ц186.
   Maruyama W., Yamamoto T., Kitani K., Carrillo M. C., Youdim M. B. H. and Naoi M. (2000b) Mechanism underlying anti-apoptotic activity of a ()) deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. 116, 181Ц191.
   Maruyama W., Youdim M. B. H. and Naoi M. (2000c) Antiapoptotic function of N-propargylamine-1(R)- and (S)-aminoindan, Rasagi- line and TV1022. Ann. N Y Acad. Sci. 939, 320Ц329.
   Maruyama W., Akao Y., Youdim M. B. H., Boulton A. A., Davis B. A. and Naoi M. (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumula- tion of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78, 727Ц735.
   Maruyama W., Takahashi T., Youdim M. B. H. and Naoi M. (2002) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109, 467Ц481.
   MaruyamaW.,Weinstock M., YoudimM. B., NagaiM. and Naoi M. (2003) Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)- (3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinester- ase-monoamine oxidase inhibitor. Neurosci. Lett. 341, 233Ц236.
   Maruyama W., Nitta A., Shamoto-Nagai M., Hirata Y., Akao Y., Youdim M. B. H., Furukawa S., Nabeshima T. and Naoi M. (2004) N- propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line- derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neu- rochem. Int. 44, 393Ц400.
   Naoi M., Maruyama W., Akao Y., Yi H. and Yamaoka Y. (2006) Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J. Neural Transm. Suppl. 67Ц77.
   Olanow C. W., Hauser R. A., Jankovic J. et al. (2008) A randomized, double-blind, placebo-controlled, delayed start study to assess ra- sagiline as a disease modifying therapy in ParkinsonТs disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov. Disord. 23, 2194Ц2201.
   Olanow C. W., Rascol O., Hauser R. et al. (2009) A double-blind, de- layed-start trial of rasagiline in ParkinsonТs disease. N. Engl. J. Med. 361, 1268Ц1278.
   Ou X. M., Lu D., Johnson C., Chen K., Youdim M. B., Rajkowska G. and Shih J. C. (2009) Glyceraldehyde-3-phosphate dehydrogenase- monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox. Res. 16, 148Ц159.
   Reynolds G. P., Elsworth J. D., Blau K., Sandler M., Lees A. J. and Stern G. M. (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 6, 542Ц544.
   Ruvolo P. P., Deng X., Carr B. K. and MayW. S. (1998) A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 273, 25436Ц25442.
   Sagi Y., Mandel S., Amit T. and Youdim M. B. (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25, 35Ц44.
   Speiser Z., Katzir O., Rehavi M., Zabarski T. and Cohen S. (1998a) Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol. Biochem. Behav. 60, 387Ц393.
   Speiser Z., Levy R. and Cohen S. (1998b) Effects of N-propargyl-1- (R)aminoindan (rasagiline) in models of motor and cognition dis- orders. J. Neural Transm. Suppl. 52, 287Ц300.
   Speiser Z., Mayk A., Eliash S. and Cohen S. (1999) Studies with ra- sagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J. Neural Transm. 106, 593Ц606.
   Sterling J., Veinberg A., Lerner D., Goldenberg W., Levy R., Youdim M. and Finberg J. (1998) (R)(+)-N-propargyl-1-aminoindan (rasagi- line) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J. Neural Transm. Suppl. 52, 301Ц305.
   Sterling J., Herzig Y., Goren T. et al. (2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phen- ethylamine as potential treatment for AlzheimerТs disease. J. Med. Chem. 45, 5260Ц5279.
   Tazik S., Johnson S., Lu D., Johnson C., Youdim M. B., Stockmeier C. A. and Ou X. M. (2009) Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone- induced brain cell apoptosis. Neurotox. Res. 15, 284Ц290.
   Tsujimoto Y. and Shimizu S. (2000) Bcl-2 family: life-or-death switch. FEBS Lett. 466, 6Ц10.
   Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O. and Youdim M. B. H. (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 18, 1471Ц1473.
   Weinstock M., Bejar C., Wang R. H., Poltyrev T., Gross A., Finberg J. and Youdim M. B. H. (2000a) TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of AlzheimerТs disease. J. Neural Transm. 60(Suppl.), S157ЦS170.
   Weinstock M., Goren T. and Youdim M. B. H. (2000b) Development of a novel neuroprotective drug (TV3326) for the treatment of Alz- heimerТs disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev Res 50, 216Ц222.
   Weinstock M., Kirschbaum-Slager N., Lazarovici P., Bejar C., Youdim M. B. H. and Shoham S. (2001) Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti- Alzheimer drugs. Ann. NY Acad. Sci. 939, 148Ц161.
   Weinstock M., Poltyrev T., Bejar C., Sagi Y. and Youdim M. B. H. (2002) TV3326, a novel cholinesterase and MAO inhibitor for AlzheimerТs disease with co-morbidity of ParkinsonТs disease and depression, in Mapping the Progress of AlzheimerТs and Parkin- sonТs Disease (Mizuno Y., Fisher A. and Hanin I., eds), pp. 199Ц 204. Kluwer Academic/Plenum Publishers, New York.
   Weinstock M., Gorodetsky E., Poltyrev T., Gross A., Sagi Y. and You- dim M. B. H. (2003) A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia co- morbid with depression and ParkinsonТs disease. Prog. Neuropsy- chopharmacol. Biol. Psychiatry 27, 555Ц561.
   Yi H., Maruyama W., Akao Y., Chen K., Iwasa K., Shih J., Youdim M. B. H. and Naoi M. (2005) N-propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N- methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural Transm. 113, 21Ц32.
   Yi H., Maruyama W., Akao Y., Takahashi T., Iwasa K., Youdim M. B. and Naoi M. (2006) N-propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salso- linol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural Transm. 113, 21Ц32.
   Yogev-Falach M., Amit T., Bar-Am O., Sagi Y., Weinstock M. and Youdim M. B. H. (2002) The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor pro- tein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 16, 1674Ц1676.
   Yogev-Falach M., Amit T., Bar-AM O. and Youdim M. B. H. (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid pre- cursor protein processing. FASEB J. 17, 2325Ц2327.
   Yogev-Falach M., Bar-Am O., Amit T., Weinreb O. and Youdim M. B. (2006) A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J. 20, 2177Ц2179.
   Yoshida T., Yamada Y., Yamamoto T. and Kuroiwa Y. (1986) Metabo- lism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 16, 129Ц136.
   Youdim M. B. H. (2003) Rasagiline: an anti-Parkinson drug with neu- roprotective activity. Future Drugs 3, 737Ц749.
   Youdim M. B. H. and Weinstock M. (2002) Molecular basis of neuro- protective activities of rasagiline and the anti Alzheimer drug, TV3326, [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl car- bamate]. Cell. Mol. Neurobiol. 21, 555Ц573.
   Youdim M. B. H., Gross A. and Finberg J. P. M. (2001a) Rasagiline [N- propargyl-1R(+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132, 500Ц 506.
   Youdim M. B. H., Wadia A., Tatton N. A. and Weinstock M. (2001b) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. NY Acad. Sci. 939, 450Ц458.
   Youdim M. B., Bar Am O., Yogev-Falach M., Weinreb O., Maruyama W., Naoi M. and Amit T. (2005) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79, 172Ц179.
   ZhuW., XieW., Pan T., Jankovic J., Li J., Youdim M. B. and LeW. (2008) Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J. Neurochem. 105, 1970Ц1978.
   
  

[ —одержание выпуска N 1 | ¬ыпуски журнала | —писок журналов ]